ArticleStem cell reports2018
MEIS1 Regulates Hemogenic Endothelial Generation, Megakaryopoiesis, and Thrombopoiesis in Human Pluripotent Stem Cells by Targeting TAL1 and FLI1.
Open access · goldAbstract read
In one paragraph
Article in Stem cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 62 citations in OpenAlex.
- The mitochondria-targeting compound PTC299 enhances megakaryocyte and platelet production.Stem cells translational medicine · 2026Article
- Generation and single-cell characterization of functional megakaryocytes derived from umbilical cord blood.Stem cell research & therapy · 2026Article
- Enhanced regenerative and developmental potential of embryonal and stem cell-derived platelets compared to adult platelets.Cell reports. Medicine · 2025Article
- ELTD1 inhibits differentiation of hemogenic endothelium progenitors from human embryonic stem cells through the HPIP-Wnt pathway.Experimental & molecular medicine · 2025Article
- Article
- Integrated Multi-Level Investigation of Friend Leukemia Integration 1 Transcription Factor as a Novel Immune-Inflammatory Biomarker in Rheumatoid Arthritis: Bridging Bioinformatics, Clinical Cohorts, and Mechanistic Validation.Journal of inflammation research · 2025Article
- Single-nuclei transcriptome analysis of IgMFrontiers in immunology · 2025Article
- Baffled-flow culture system enables the mass production of megakaryocytes from human embryonic stem cells by enhancing mitochondrial function.Cell proliferation · 2023Article
- ZEB2 and MEIS1 independently contribute to hematopoiesis via early hematopoietic enhancer activation.iScience · 2023Article
- Insight into microRNAs' involvement in hematopoiesis: current standing point of findings.Stem cell research & therapy · 2023Review
- Cross-species transcriptomics reveals bifurcation point during the arterial-to-hemogenic transition.Communications biology · 2023Article
- Article
- Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma.Nature communications · 2023Article
- Meis1 Controls the Differentiation of Eye Progenitor Cells and the Formation of Posterior Poles during Planarian Regeneration.International journal of molecular sciences · 2023Article
- Augmented Production of Platelets From Cord Blood With Euchromatic Histone Lysine Methyltransferase Inhibition.Stem cells translational medicine · 2022Article
- Elucidating the importance and regulation of key enhancers for human MEIS1 expression.Leukemia · 2022Article
- The Differentiation of Pluripotent Stem Cells towards Endothelial Progenitor Cells - Potential Application in Pulmonary Arterial Hypertension.International journal of stem cells · 2022Article
- The heterogeneity of megakaryocytes and platelets and implications for ex vivo platelet generation.Stem cells translational medicine · 2021Review
- Definitive hematopoietic stem cells minimally contribute to embryonic hematopoiesis.Cell reports · 2021Article
- Characterization of Cellular Heterogeneity and an Immune Subpopulation of Human Megakaryocytes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Hongtao WangState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China; Center for Stem Cell Medicine, Chinese Academy of Medical Sciences & Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin 300020, China.
Cuicui LiuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China; Center for Stem Cell Medicine, Chinese Academy of Medical Sciences & Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin 300020, China.
Xin LiuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China; Center for Stem Cell Medicine, Chinese Academy of Medical Sciences & Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin 300020, China.
Mengge WangState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China; Center for Stem Cell Medicine, Chinese Academy of Medical Sciences & Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin 300020, China.
Dan WuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China; Center for Stem Cell Medicine, Chinese Academy of Medical Sciences & Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin 300020, China.
Jie GaoState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China; Center for Stem Cell Medicine, Chinese Academy of Medical Sciences & Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin 300020, China.
Pei SuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China; Center for Stem Cell Medicine, Chinese Academy of Medical Sciences & Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin 300020, China.
Tatsutoshi NakahataCenter for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.
Wen ZhouSchool of Basic Medical Science and Cancer Research Institute, Central South University, Changsha 410013, China.
Yuanfu XuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China; Center for Stem Cell Medicine, Chinese Academy of Medical Sciences & Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin 300020, China.
Lihong ShiState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China; Center for Stem Cell Medicine, Chinese Academy of Medical Sciences & Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin 300020, China.
Feng MaState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China; Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu 610052, China. Electronic address: mafeng@hotmail.co.jp.
Jiaxi ZhouState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China; Center for Stem Cell Medicine, Chinese Academy of Medical Sciences & Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin 300020, China. Electronic address: zhoujx@ihcams.ac.cn.
Institute of Hematology & Blood Diseases Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNCentral South University · CNKyoto University · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human pluripotent stem cells (hPSCs) provide an unlimited source for generating various kinds of functional blood cells. However, efficient strategies for generating large-scale functional blood cells from hPSCs are still lacking, and the mechanism underlying human hematopoiesis remains largely unknown. In this study, we identified myeloid ectopic viral integration site 1 homolog (MEIS1) as a crucial regulator of hPSC early hematopoietic differentiation. MEIS1 is vital for specification of APLNR
Indexed as
Pluripotent Stem CellsApelin ReceptorsCell DifferentiationGene Expression Regulation, DevelopmentalHemangioblastsHumansMegakaryocytesMyeloid Ecotropic Viral Integration Site 1 ProteinProto-Oncogene Protein c-fli-1T-Cell Acute Lymphocytic Leukemia Protein 1ThrombopoiesisApelin ReceptorsAPLNR protein, humanFLI1 protein, humanMEIS1 protein, humanMyeloid Ecotropic Viral Integration Site 1 ProteinProto-Oncogene Protein c-fli-1TAL1 protein, humanT-Cell Acute Lymphocytic Leukemia Protein 1FLI1hematopoiesishemogenic endothelialhPSCsmegakaryopoiesisMEIS1TAL1thrombopoiesis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.